A highly selective, first-in-class Pin1 degrader is developed which demonstrated robust PKPD in vivo with sustained target engagement observed following a single dose and it is demonstrated that Pin1 degraders drive significant tumor growth inhibition (TGI) across multiple PDAC efficacy models.
Morgan B. O'Shea, Guo-Sen B. Ye, Melvyn B. Chow et al.· Clinical Cancer Research· 0 citations
Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in multiple tumors including...
Krista Goodman, Eva B. d'Hennezel, Morgan B. O'Shea et al.· Clinical Cancer Research· 0 citations
A highly selective, first-in-class Pin1 degrader is developed which demonstrated robust PKPD in vivo with sustained target engagement observed following a single dose and it is demonstrated that Pin1 degraders drive significant tumor growth inhibition (TGI) across multiple PDAC efficacy models.
Morgan B. O'Shea, Guo-Sen B. Ye, Melvyn B. Chow et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.